Stock Analysis

The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

CPSE:HLUN B 1 Year Share Price vs Fair Value
CPSE:HLUN B 1 Year Share Price vs Fair Value
Explore H. Lundbeck's Fair Values from the Community and select yours

It's been a pretty great week for H. Lundbeck A/S (CPH:HLUN B) shareholders, with its shares surging 12% to kr.39.06 in the week since its latest quarterly results. It was a credible result overall, with revenues of kr.6.0b and statutory earnings per share of kr.0.97 both in line with analyst estimates, showing that H. Lundbeck is executing in line with expectations. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

earnings-and-revenue-growth
CPSE:HLUN B Earnings and Revenue Growth August 16th 2025

Taking into account the latest results, the consensus forecast from H. Lundbeck's ten analysts is for revenues of kr.24.4b in 2025. This reflects a modest 3.9% improvement in revenue compared to the last 12 months. Per-share earnings are expected to climb 11% to kr.3.91. In the lead-up to this report, the analysts had been modelling revenues of kr.24.1b and earnings per share (EPS) of kr.3.66 in 2025. So the consensus seems to have become somewhat more optimistic on H. Lundbeck's earnings potential following these results.

View our latest analysis for H. Lundbeck

There's been no major changes to the consensus price target of kr.47.29, suggesting that the improved earnings per share outlook is not enough to have a long-term positive impact on the stock's valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values H. Lundbeck at kr.71.00 per share, while the most bearish prices it at kr.38.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the H. Lundbeck's past performance and to peers in the same industry. The period to the end of 2025 brings more of the same, according to the analysts, with revenue forecast to display 7.9% growth on an annualised basis. That is in line with its 6.6% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 5.3% annually. So although H. Lundbeck is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.

Advertisement

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards H. Lundbeck following these results. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for H. Lundbeck going out to 2027, and you can see them free on our platform here..

Before you take the next step you should know about the 1 warning sign for H. Lundbeck that we have uncovered.

Valuation is complex, but we're here to simplify it.

Discover if H. Lundbeck might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About CPSE:HLUN B

H. Lundbeck

Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.

Undervalued with solid track record.

Advertisement